Related Experiment Video
Updated: Sep 30, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor
1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2279, USA.
Abstract:
Numerous reports suggest that use of nonsteroidal anti-inflammatory drugs (NSAIDs) decrease mortality from colorectal cancer. To better understand all of the mechanisms underlying this effect, the global pattern of gene expression in colon carcinoma cells following treatment with NS-398, a selective cyclo-oxygenase-2 inhibitor was evaluated. We utilized suppression subtractive hybridization combined with differential screening to identify genes whose expression was affected following treatment. Among the subtracted cDNA fragments confirmed as differentially expressed, there were two which are known to be involved in the regulation of cell adhesion (human FAT and proto-cadherin-7). We identified two other genes whose levels were decreased and these are known to be involved in the regulation of cell proliferation (cyclin K and p-100). We identified additional genes which are involved in different signaling pathways which regulate programmed cell death (Dynamin 2, Pdcd4 and LIP.1). These results provide evidence that some of the effects of NS-398 on carcinoma cells may be due to modulation of genes which regulate programmed cell death, cell proliferation and cell-cell communication. Additional studies are underway to determine the biological function of the novel genes that were identified.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce colorectal cancer mortality. This study investigated how NS-398, a cyclo-oxygenase-2 inhibitor, alters gene expression in colon cancer cells, revealing impacts on cell adhesion, proliferation, and programmed cell death.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are linked to reduced colorectal cancer mortality.
- The precise molecular mechanisms behind NSAIDs' anti-cancer effects require further elucidation.
- Selective cyclo-oxygenase-2 (COX-2) inhibitors represent a class of NSAIDs with potential therapeutic applications.
Purpose of the Study:
- To investigate the global gene expression patterns in colon carcinoma cells treated with NS-398, a selective COX-2 inhibitor.
- To identify specific genes and pathways modulated by NS-398 treatment.
- To understand the molecular basis of NS-398's effects on cancer cells.
Main Methods:
- Utilized suppression subtractive hybridization (SSH) combined with differential screening.
- Analyzed gene expression changes in colon carcinoma cells after NS-398 treatment.
- Confirmed differentially expressed genes involved in key cellular processes.
Main Results:
- Identified alterations in genes regulating cell adhesion (human FAT, proto-cadherin-7).
- Observed decreased expression of genes involved in cell proliferation (cyclin K, p-100).
- Detected modulation of genes associated with programmed cell death pathways (Dynamin 2, Pdcd4, LIP.1).
Conclusions:
- NS-398 treatment impacts colon carcinoma cells by modulating genes controlling programmed cell death, cell proliferation, and cell-cell communication.
- These findings provide insights into the molecular mechanisms of selective COX-2 inhibitors in colorectal cancer.
- Further research is warranted to explore the functions of novel identified genes.
